Australia Optic Neuritis Therapeutics Market Report 2023 to 2030

Australia Optic Neuritis Therapeutics Market Analysis

$ 3999

Australia Optic Neuritis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rising incidence of optic neuritis is anticipated to fuel market expansion on a global scale. The rising prevalence of multiple sclerosis may be a major market driver. The usage of intravenous steroids such as prednisone, prednisolone, and others are anticipated to increase, which will help support market expansion. Major global players in Optic Neuritis Therapeutics Market are AbbVie Inc., Bausch & Lomb Incorporated, Boehringer Ingelheim International GmbH, Novartis AG, Merck & Co., Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi USA, Teva Pharmaceuticals Industries Ltd., GSK plc, Pfizer, Akorn Operating Company LLC, AdvaCare Pharma, Bristol- Myers Squibb Company, Jubilant Cadista Pharmaceuticals Inc., Amneal Pharmaceuticals LLC., Viatris Inc., and Novitium Pharma.

ID: IN10AURD055 CATEGORY: Rare Diseases GEOGRAPHY: Australia AUTHOR: Gaurav Bhongale

Buy Now

Australia Optic Neuritis Therapeutics Market Analysis Summary

Australia Optic Neuritis Therapeutics Market is valued at around $42.6 Mn in 2022 and is projected to reach $67.9 Mn by 2030, exhibiting a CAGR of 6% during the forecast period 2023-2030.

Optic neuritis is the medical term for an optic nerve swelling or irritation. It is also frequently referred to as ocular papillitis and retro tubular neuritis. The optic nerves are a type of nerve fibre that may transmit visual data from the eye to the brain. In most cases, the inflammation only results in temporary blindness in one eye and damage to the optic nerve. There are two types of optic neuritis: paediatric and adult, which are distinguished by the age range of those who have been diagnosed with it. The usual methods for diagnosing optic neuritis are physical examination and medical history. Early therapy is critically vital in this disorder due to the lifetime risk of losing human eye eyesight. Optic neuritis most frequently manifests as eye pain and dyschromatopsia, or incorrect colour perception.

The rising incidence of optic neuritis is anticipated to fuel market expansion on a global scale. The rising prevalence of multiple sclerosis may be a major market driver. The usage of intravenous steroids such as prednisone, prednisolone, and others is anticipated to increase, which will help support market expansion. Additionally, it is anticipated that growing research into therapies for optic neuritis will boost market growth. Major global players in Optic Neuritis Therapeutics Market are AbbVie Inc., Bausch & Lomb Incorporated, Boehringer Ingelheim International GmbH, Novartis AG, Merck & Co., Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi USA, Teva Pharmaceuticals Industries Ltd., GSK plc, Pfizer, Akorn Operating Company LLC, AdvaCare Pharma, Bristol- Myers Squibb Company, Jubilant Cadista Pharmaceuticals Inc., Amneal Pharmaceuticals LLC., Viatris Inc., and Novitium Pharma.

Market Dynamics

Market Drivers

increasing frequency of ocular diseases

Optic neuritis is becoming more widely known as a result of the condition's rising prevalence in various parts of the world. Therefore, it is anticipated that as patients become more knowledgeable about optic neuritis, the market would expand.

expansion of traumatic injuries

The increasing prevalence of the condition in the area has a substantial impact on the market's growth rate for optic neuritis.

an increase in the population's age

The main drivers of the market include an ageing population, a growth in the number of people with multiple sclerosis, rising awareness, and reasonable prices.

Notable deals in Australia Optic Neuritis Therapeutics Market

In October 2022: A $ 1.6 Mn grant has been given to Trethera to continue working on TRE-515, a potential treatment for optic neuritis, a frequent symptom of multiple sclerosis (MS).

In August 2022: the U.S. FDA granted orphan drug designation to Trethera Corporation’s experimental oral therapy TRE-515 for demyelinating optic neuritis, an eye condition that may progress to multiple sclerosis (MS) or occur during the disease course.

Key players

Novartis Pfizer Sanofi Biogen Catalyst Biosciences uniQure Ionis Pharmaceuticals Alnylam Pharmaceuticals Intercept Pharmaceuticals Roche

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Australia Optic Neuritis Therapeutics Market

By Treatment Type

Steroidal Therapy
Immunomodulators therapy
Other Treatment Types

By Route of Administration

Oral Corticosteroids
Intravenous Corticosteroids

By End User

Hospitals
Research Institutes
Specialty Clinics

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.